ELRIG Bioprocess Conference ELRIG Bioprocess Conference

The ELRIG meeting on High Throughput BioProcess development is only a few weeks away.
25 May 2011

GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication

GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip
19 January 2011

Researchers visualise herpes virus's tactical manoeuvre Researchers visualise herpes virus's tactical manoeuvre

For the first time, researchers have developed a 3D picture of a herpes virus protein interacting with a key part of the human cellular machinery, enhancing our understanding of how it hijacks human cells to spread infection and opening up new possibilities for stepping in to prevent or treat infection. This discovery uncovers one of the many tactical manoeuvres employed by the virus.
06 January 2011

Manufacturing safety raises concern Manufacturing safety raises concern

Last week, pharmaceutical heads met as a result of a drug recall after a mix up of breast cancer pills. The mishap raises the question: ‘Is there enough regulation to protect patients?’
21 October 2010

Grass looking greener for malaria patients Grass looking greener for malaria patients

The frontline malaria treatment artemisinin could soon be treating more people for less cost, thanks to a research collaboration between Bradford and Shanghai.
06 October 2010

Genome maps could help predict risk of breast cancer Genome maps could help predict risk of breast cancer

The combined effects of numerous single-letter changes in several genes could be used to predict a woman’s risk of developing the most common form of breast cancer – oestrogen-receptor-positive breast cancer.
07 September 2010

MorphoSys initiates program against drug-resistant MRSA infections MorphoSys initiates program against drug-resistant MRSA infections

MorphoSys AG has announced a new proprietary development program against novel infectious disease targets. As part of this initiative, MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics.
03 September 2010

CRT and Bayer Schering Pharma to investigate gynaecological and oncological diseases CRT and Bayer Schering Pharma to investigate gynaecological and oncological diseases

Cancer Research Technology has signed an agreement with Bayer Schering Pharma AG, Germany, to evaluate new leptin antagonist peptides as potential experimental treatments, initially in the area of gynaecological diseases, including cancer.
25 August 2010

Body clock drugs could ease psychiatric disorders Body clock drugs could ease psychiatric disorders

Researchers have used a drug to reset and restart the 24 hour body clock of mice, which could eventually help with human difficulties including some psychiatric disorders, jet lag and the health impacts of shift work.
24 August 2010

CRT and ValiRx sign prostate cancer treatment deal CRT and ValiRx sign prostate cancer treatment deal

Cancer Research Technology has signed a deal to provide biotech company ValiRx PLC with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.
16 August 2010